At the
forefront.

A rapidly evolving subspecialty

Recognized as a world leader in the diagnosis and treatment of autoimmune neurologic disorders and demyelinating disease, Mayo Clinic mounts unmatched resources for uncovering novel syndromes, developing new diagnostic biomarkers and unique laboratory tests.

Autoimmune neurology is a rapidly evolving subspecialty driven by the discovery that the immune system can target virtually any structure within the central or peripheral nervous system. These conditions manifest as disorders previously thought to be independent and unrelated.

For the spectrum of autoimmune neurological disorders, where an early and accurate diagnosis is paramount, our testing approaches to effectively diagnose and guide treatment for these patients is unparalleled.


A history of innovation and discovery

The Mayo Clinic Neuroimmunology Laboratory was the first to introduce comprehensive serological evaluations for the diagnosis of paraneoplastic neurologic autoimmune disorders, a group of disorders in which unusual neurologic signs and symptoms are the initial manifestations of cancer.

The laboratory continues to discover and clinically validate novel autoantibody profiles that inform neurological decision-making and guide the search for cancer. 

An accurate and timely diagnosis is critical

Identifying the root cause can lead to a possible cure versus temporary relief. Early intervention may allow reversal of deficits in many patients and prevention of future disability. Antibody results may direct a targeted search for malignancy


The Power of Discovery

Autoimmune neurological disorders can often be treated, sometimes with full restoration of function. However, because the symptoms mimic other conditions, autoimmune neurological disorders are frequently misdiagnosed, resulting in an irreversible loss of function.

Additional Resources

By MCL Education • December 14, 2020
By Alyssa Frank • August 19, 2020
By MCL Education • June 2, 2020
By MCL Education • August 22, 2019
By Mayo Clinic News Network • July 31, 2019